Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.
Baert L, van 't Klooster G, Dries W, François M, Wouters A, Basstanie E, Iterbeke K, Stappers F, Stevens P, Schueller L, Van Remoortere P, Kraus G, Wigerinck P, Rosier J. Baert L, et al. Among authors: wigerinck p. Eur J Pharm Biopharm. 2009 Aug;72(3):502-8. doi: 10.1016/j.ejpb.2009.03.006. Epub 2009 Mar 27. Eur J Pharm Biopharm. 2009. PMID: 19328850
Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies.
Van Gyseghem E, Pendela M, Baert L, Rosier J, Van 't Klooster G, De Man H, Bouche MP, Schueller L, Van Remoortere P, Wigerinck P, Adams E, Hoogmartens J, Van den Mooter G. Van Gyseghem E, et al. Among authors: wigerinck p. Eur J Pharm Biopharm. 2008 Nov;70(3):853-60. doi: 10.1016/j.ejpb.2008.06.030. Epub 2008 Jul 9. Eur J Pharm Biopharm. 2008. PMID: 18657611
Dog model with implanted pump to test boosters for antiretroviral medication.
Schueller L, Baert L, Lachau-Durand S, Borghys H, Clessens E, Van Den Mooter G, Van Gyseghem E, Jonckers TH, Van Remoortere P, Wigerinck P, Rosier J. Schueller L, et al. Among authors: wigerinck p. Int J Pharm. 2008 May 1;355(1-2):45-52. doi: 10.1016/j.ijpharm.2007.09.025. Epub 2007 Sep 25. Int J Pharm. 2008. PMID: 18082980
Development of an implantable infusion pump for sustained anti-HIV drug administration.
Baert L, Schueller L, Tardy Y, Macbride D, Klooster Gv, Borghys H, Clessens E, Van Den Mooter G, Van Gyseghem E, Van Remoortere P, Wigerinck P, Rosier J. Baert L, et al. Among authors: wigerinck p. Int J Pharm. 2008 May 1;355(1-2):38-44. doi: 10.1016/j.ijpharm.2008.01.029. Epub 2008 Jan 24. Int J Pharm. 2008. PMID: 18337029
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
Bonfanti JF, Meyer C, Doublet F, Fortin J, Muller P, Queguiner L, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, van Remoortere P, Janssens F, Wigerinck P, Andries K. Bonfanti JF, et al. Among authors: wigerinck p. J Med Chem. 2008 Feb 28;51(4):875-96. doi: 10.1021/jm701284j. Epub 2008 Feb 7. J Med Chem. 2008. PMID: 18254606
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
Surleraux DL, Tahri A, Verschueren WG, Pille GM, de Kock HA, Jonckers TH, Peeters A, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB. Surleraux DL, et al. Among authors: wigerinck pb. J Med Chem. 2005 Mar 24;48(6):1813-22. doi: 10.1021/jm049560p. J Med Chem. 2005. PMID: 15771427
In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.
Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, Vermeiren K, Rosenquist A, Edlund M, Samuelsson B, Vrang L, de Kock H, Wigerinck P, Raboisson P, Simmen K. Lin TI, et al. Among authors: wigerinck p. Antimicrob Agents Chemother. 2009 Apr;53(4):1377-85. doi: 10.1128/AAC.01058-08. Epub 2009 Jan 26. Antimicrob Agents Chemother. 2009. PMID: 19171797 Free PMC article.
Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, Lindström S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P. Vendeville S, et al. Among authors: wigerinck p. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6189-93. doi: 10.1016/j.bmcl.2008.10.004. Epub 2008 Oct 5. Bioorg Med Chem Lett. 2008. PMID: 18954982
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Surleraux DL, de Kock HA, Verschueren WG, Pille GM, Maes LJ, Peeters A, Vendeville S, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB. Surleraux DL, et al. Among authors: wigerinck pb. J Med Chem. 2005 Mar 24;48(6):1965-73. doi: 10.1021/jm049454n. J Med Chem. 2005. PMID: 15771440
29 results